Eligible Medicare members can now access select FDA-approved GLP-1 medications including Wegovy and Zepbound through the Medicare GLP-1 Bridge Program, running July 1, 2026 through December 31, 2027
Conte C, et al
Celebrate small wins along the way, and remind yourself that every step forwardeven a small onebrings you closer to your goal
Sibutramine, a drug no longer available on the market, was an effective weight-loss drug with metabolism-boosting effects and also acted as an appetite suppressant
3 Consequently, conditions linked with obesity, type 2 diabetes, and metabolic syndrome are becoming increasingly prevalent
Lawsuits continue against makers of GLP-1 weight-loss drugs over side effects ranging from extreme vomiting to what some plaintiffs describe as eye strokes, according to multiple media reports